Home > Archive > 2017 > 3

Volume 36, Number 3, pages 10-13

The Cadillac Combination for Type 2 Diabetes: A GLP-1 receptor Agonist and a SGLT2 Inhibitor

David S. H. Bell, MB, FACE, FACP Professor of Medicine (retired) University of Alabama and Southside Endocrinology Birmingham, Alabama, and Edison Goncalves, MD, FACE, FACP Diabetes and Thyroid Associates Birmingham, Alabama

In choosing drugs to treat Type 2 diabetes, insulin, sulfonylureas and other secretagogues are not a prudent initial choice due to the increased risk of hypoglycemia associated with their use. Similarly, drugs that lead to weight gain (insulin, secretagogues, thiazolidinediones) should be avoided due to the potential of increasing insulin resistance.

Drug treatmentSodium-glucose cotransporter 2 inhibitors